| Primary information |
|---|
| ID | antitb_1992, |
| Name | 26352292 |
| N-Terminal modification | VpAmp1.1 |
| C-Terminal Modification | FFLLSLIPSAISAIKKI |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 17 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC= 5.4 ± 1.7 µM |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall |
| PMID | NA |
| Year of Publication | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1993, |
| Name | 26352292 |
| N-Terminal modification | VpAmp1.1 |
| C-Terminal Modification | FFLLSLIPSAISAIKKI |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 17 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis MDR |
| Cell Line | MIC= 8.6 ± 3.3 µM |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | Cell wall |
| PMID | NA |
| Year of Publication | Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus agalactiae |
Tertiary Structure
(Technique) | Not Predicted), |